The global circulating tumor cells market size is estimated to reach USD 24.96 billion by 2030, expanding at a CAGR of 12.2% from 2025 to 2030. This is attributed to rising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.
In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management - early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.
The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.
However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market’s growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.
This product will be delivered within 2 business days.
In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management - early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.
The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.
However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market’s growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.
Circulating Tumor Cells Market Report Highlights
- Based on technology, The CTC detection and enrichment methods segment accounted for the largest revenue share of 40.92% in 2024 owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
- CTC analysis is expected to register the fastest CAGR during the forecast period due to the growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
- Based on application, the research segment dominated the market in 2024 and it is expected to witness the fastest CAGR from 2025 to 2030
- Kits & reagent dominated the product segment in 2024, and it is expected to witness the fastest growth in forecast period of 2025-2030
- Based on specimen, the blood segment dominated the market in 2024. The other body fluids segment is expected to witness the fastest CAGR from 2025 to 2030
- Based on end-use, the research & academic institutes segment dominated the market in 2024 due to increasing focus on research and development activities for cancer diagnosis and treatment
- North America dominated the CTC market in 2024, owing to factors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
- Asia Pacific is expected to register the fastest CAGR over the forecast period due to several companies expanding their presence in countries like Japan
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This Report Addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Product
1.2.4. Specimen
1.2.5. End use
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Circulating Tumor Cells Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Advancements in chip technology
3.2.1.2. Expanding applications of CTCs
3.2.1.3. Growing demand for early and rapid cancer diagnosis
3.2.1.4. Growing incidence of cancer
3.2.2. Market restraint analysis
3.2.2.1. Consistency-related challenges in CTC detection and enrichment
3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
3.2.2.3. Lower applicability of CTCs in rare cancers
3.3. Circulating Tumor Cells Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis
4.1. Technology Segment Dashboard
4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. CTC Detection & Enrichment Methods
4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2. Immunocapture (Label-based)
4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2.2. Positive Selection
4.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2.3. Negative Selection
4.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3. Size-based Separation (Label-free)
4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3.2. Membrane-based
4.4.1.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3.3. Microfluidic-based
4.4.1.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.4. Density-based Separation (Label-free)
4.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.5. Combined Methods
4.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. CTC Direct Detection Methods
4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.2. SERS
4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.3. Microscopy
4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. CTC Analysis
4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. Global Circulating Tumor Cells Market Application Movement Analysis
5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Clinical
5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.1.2. Risk Assessment
5.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.1.3. Screening and Monitoring
5.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2. Research
5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
5.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2.3. Drug/Therapy Development
5.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis
6.1. Product Segment Dashboard
6.2. Global Circulating Tumor Cells Market Product Movement Analysis
6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Kits & reagents
6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
6.4.2. Blood collection tubes
6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3. Devices or systems
6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis
7.1. Specimen Segment Dashboard
7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Blood
7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
7.4.2. Bone marrow
7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. Other body fluids
7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Circulating Tumor Cells Market: End Use Estimates & Trend Analysis
8.1. End Use Segment Dashboard
8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Research and academic institutes
8.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
8.4.2. Hospital and clinics
8.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.4.3. Diagnostic centers
8.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
9.3.1.5. Target disease prevalence
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
9.3.3.5. Target disease prevalence
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
9.4.1.5. Target disease prevalence
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
9.4.7.5. Target disease prevalence
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
9.4.8.5. Target disease prevalence
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
9.5.1.5. Target disease prevalence
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
9.5.4.5. Target disease prevalence
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
9.5.5.5. Target disease prevalence
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
9.5.6.5. Target disease prevalence
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
9.6.1.5. Target disease prevalence
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
9.6.2.5. Target disease prevalence
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
9.7.1.5. Target disease prevalence
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
9.7.2.5. Target disease prevalence
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
9.7.3.5. Target disease prevalence
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
9.7.4.5. Target disease prevalence
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company position analysis, 2024
10.3.4. QIAGEN
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Bio-Techne Corp.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Precision Medicine Group, LLC.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Bio-Rad Laboratories, Inc.
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Natera, Inc.
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Illumina, Inc.
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Cell Microsystems
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Greiner Bio One International GmbH
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Ikonisys Inc.
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Miltenyi Biotec
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Creative Bioarray
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product benchmarking
10.3.14.4. Strategic initiatives
10.3.15. BioFluidica
10.3.15.1. Company overview
10.3.15.2. Financial performance
10.3.15.3. Product benchmarking
10.3.15.4. Strategic initiatives
10.3.16. Abnova Corporation
10.3.16.1. Company overview
10.3.16.2. Financial performance
10.3.16.3. Product benchmarking
10.3.16.4. Strategic initiatives
10.3.17. Biolidics Limited
10.3.17.1. Company overview
10.3.17.2. Financial performance
10.3.17.3. Product benchmarking
10.3.17.4. Strategic initiatives
10.3.18. Creativ MicroTech, Inc.
10.3.18.1. Company overview
10.3.18.2. Financial performance
10.3.18.3. Product benchmarking
10.3.18.4. Strategic initiatives
10.3.19. LungLife AI
10.3.19.1. Company overview
10.3.19.2. Financial performance
10.3.19.3. Product benchmarking
10.3.19.4. Strategic initiatives
10.3.20. Epic Sciences
10.3.20.1. Company overview
10.3.20.2. Financial performance
10.3.20.3. Product benchmarking
10.3.20.4. Strategic initiatives
10.3.21. Rarecells Diagnostics
10.3.21.1. Company overview
10.3.21.2. Financial performance
10.3.21.3. Product benchmarking
10.3.21.4. Strategic initiatives
10.3.22. ScreenCell
10.3.22.1. Company overview
10.3.22.2. Financial performance
10.3.22.3. Product benchmarking
10.3.22.4. Strategic initiatives
10.3.23. Menarini Silicon Biosystems
10.3.23.1. Company overview
10.3.23.2. Financial performance
10.3.23.3. Product benchmarking
10.3.23.4. Strategic initiatives
10.3.24. APPLIED DNA SCIENCES, INC.
10.3.24.1. Company overview
10.3.24.2. Financial performance
10.3.24.3. Product benchmarking
10.3.24.4. Strategic initiatives
10.3.25. Sysmex Corporation
10.3.25.1. Company overview
10.3.25.2. Financial performance
10.3.25.3. Product benchmarking
10.3.25.4. Strategic initiatives
10.3.26. STEMCELL Technologies, Inc.
10.3.26.1. Company overview
10.3.26.2. Financial performance
10.3.26.3. Product benchmarking
10.3.26.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 3 North America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 4 North America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 5 North America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 6 North America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 7 North America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 8 U.S. circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 9 U.S. circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 10 U.S. circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 11 U.S. circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 12 U.S. circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 13 Canada circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 14 Canada circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 15 Canada circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 16 Canada circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 17 Canada circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 18 Mexico circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 19 Mexico circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 20 Mexico circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 21 Mexico circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 22 Mexico circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 23 Europe circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 24 Europe circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 25 Europe circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 26 Europe circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 27 Europe circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 28 Europe circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 29 UK circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 30 UK circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 31 UK circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 32 UK circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 33 UK circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 34 Germany circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 35 Germany circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 36 Germany circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 37 Germany circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 38 Germany circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 39 Italy circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 40 Italy circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 41 Italy circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 42 Italy circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 43 Italy circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 44 France circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 45 France circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 46 France circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 47 France circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 48 France circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 49 Spain circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 50 Spain circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 51 Spain circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 52 Spain circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 53 Spain circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 54 Sweden circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 55 Sweden circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 56 Sweden circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 57 Sweden circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 58 Sweden circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 59 Denmark circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 60 Denmark circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 61 Denmark circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 62 Denmark circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 63 Denmark circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 64 Norway circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 65 Norway circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 66 Norway circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 67 Norway circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 68 Norway circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 69 Asia Pacific circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 70 Asia Pacific circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 71 Asia Pacific circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 72 Asia Pacific circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 73 Asia Pacific circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 74 Asia Pacific circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 75 China circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 76 China circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 77 China circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 78 China circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 79 China circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 80 Japan circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 81 Japan circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 82 Japan circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 83 Japan circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 84 Japan circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 85 India circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 86 India circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 87 India circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 88 India circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 89 India circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 90 South Korea circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 91 South Korea circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 92 South Korea circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 93 South Korea circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 94 South Korea circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 95 Australia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 96 Australia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 97 Australia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 98 Australia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 99 Australia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 100 Thailand circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 101 Thailand circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 102 Thailand circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 103 Thailand circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 104 Thailand circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 105 Latin America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 106 Latin America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 107 Latin America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 108 Latin America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 109 Latin America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 110 Latin America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 111 Brazil circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 112 Brazil circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 113 Brazill circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 114 Brazil circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 115 Brazil circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 116 Argentina circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 117 Argentina circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 118 Argentina circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 119 Argentina circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 120 Argentina circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 121 Middle East Africa circulating tumor cells market, by region, 2018 - 2030 (USD Million)
Table 122 Middle East Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 123 Middle East Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 124 Middle East Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 125 Middle East Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 126 Middle East Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 127 South Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 128 South Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 129 South Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 130 South Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 131 South Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 132 Saudi Arabia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 133 Saudi Arabia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 134 Saudi Arabia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 135 Saudi Arabia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 136 Saudi Arabia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 137 UAE circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 138 UAE circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 139 UAE circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 140 UAE circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 141 UAE circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
Table 142 Kuwait circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
Table 143 Kuwait circulating tumor cells market, by application, 2018 - 2030 (USD Million)
Table 144 Kuwait circulating tumor cells market, by product, 2018 - 2030 (USD Million)
Table 145 Kuwait circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
Table 146 Kuwait circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Circulating tumor cells market: market outlook
Fig. 9 Circulating tumor cells competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Circulating tumor cells market driver impact
Fig. 15 Circulating tumor cells market restraint impact
Fig. 16 Circulating tumor cells market strategic initiatives analysis
Fig. 17 Circulating tumor cells market: Technology movement analysis
Fig. 18 Circulating tumor cells market: Technology outlook and key takeaways
Fig. 19 CTC detection & enrichment methods market estimates and forecast, 2018 - 2030
Fig. 20 Immunocapture (label-based) estimates and forecast, 2018 - 2030
Fig. 21 Positive selection market estimates and forecast, 2018 - 2030
Fig. 22 Negative selection estimates and forecast, 2018 - 2030
Fig. 23 Size-based separation (label-free) market estimates and forecast, 2018 - 2030
Fig. 24 Membrane-based estimates and forecast, 2018 - 2030
Fig. 25 Microfluidic-based estimates and forecast, 2018 - 2030
Fig. 26 Density-based Separation (Label-free) estimates and forecast, 2018 - 2030
Fig. 27 Combined Methods estimates and forecast, 2018 - 2030
Fig. 28 CTC direct detection methods estimates and forecast, 2018 - 2030
Fig. 29 SERS estimates and forecast, 2018 - 2030
Fig. 30 Microscopy estimates and forecast, 2018 - 2030
Fig. 31 Others estimates and forecast, 2018 - 2030
Fig. 32 CTC Analysis estimates and forecast, 2018 - 2030
Fig. 33 Circulating tumor cells Market: Application movement Analysis
Fig. 34 Circulating tumor cells market: Application outlook and key takeaways
Fig. 35 Clinical/ Liquid Biopsy market estimates and forecasts, 2018 - 2030
Fig. 36 Risk Assessment market estimates and forecasts, 2018 - 2030
Fig. 37 Screening and Monitoring market estimates and forecasts, 2018 - 2030
Fig. 38 Research market estimates and forecasts, 2018 - 2030
Fig. 39 Cancer Stem Cell & Tumorogenesis Research market estimates and forecasts, 2018 - 2030
Fig. 40 Drug/Therapy Development market estimates and forecasts, 2018 - 2030
Fig. 41 Circulating tumor cells Market: Product movement Analysis
Fig. 42 Circulating tumor cells market: Product outlook and key takeaways
Fig. 43 Kits & reagents market estimates and forecasts, 2018 - 2030
Fig. 44 Blood collection tubes market estimates and forecasts, 2018 - 2030
Fig. 45 Devices or Systems market estimates and forecasts, 2018 - 2030
Fig. 46 Circulating tumor cells Market: Specimen movement Analysis
Fig. 47 Circulating tumor cells market: Specimen outlook and key takeaways
Fig. 48 Blood market estimates and forecasts, 2018 - 2030
Fig. 49 Bone marrow market estimates and forecasts, 2018 - 2030
Fig. 50 Other body fluids market estimates and forecasts, 2018 - 2030
Fig. 51 Circulating tumor cells Market: End use movement Analysis
Fig. 52 Circulating tumor cells market: End use outlook and key takeaways
Fig. 53 Research and academic institutes market estimates and forecasts, 2018 - 2030
Fig. 54 Hospital and clinics market estimates and forecasts, 2018 - 2030
Fig. 55 Diagnostic centers market estimates and forecasts, 2018 - 2030
Fig. 56 Global circulating tumor cells market: Regional movement analysis
Fig. 57 Global circulating tumor cells market: Regional outlook and key takeaways
Fig. 58 North America, by country
Fig. 59 North America
Fig. 60 North America market estimates and forecasts, 2018 - 2030
Fig. 61 U.S. country dynamics
Fig. 62 U.S. market estimates and forecasts, 2018 - 2030
Fig. 63 Canada country dynamics
Fig. 64 Canada market estimates and forecasts, 2018 - 2030
Fig. 65 Mexico country dynamics
Fig. 66 Mexico market estimates and forecasts, 2018 - 2030
Fig. 67 Europe market estimates and forecasts, 2018 - 2030
Fig. 68 UK country dynamics
Fig. 69 UK market estimates and forecasts, 2018 - 2030
Fig. 70 Germany country dynamics
Fig. 71 Germany market estimates and forecasts, 2018 - 2030
Fig. 72 France country dynamics
Fig. 73 France market estimates and forecasts, 2018 - 2030
Fig. 74 Italy country dynamics
Fig. 75 Italy market estimates and forecasts, 2018 - 2030
Fig. 76 Spain country dynamics
Fig. 77 Spain market estimates and forecasts, 2018 - 2030
Fig. 78 Denmark country dynamics
Fig. 79 Denmark market estimates and forecasts, 2018 - 2030
Fig. 80 Sweden country dynamics
Fig. 81 Sweden market estimates and forecasts, 2018 - 2030
Fig. 82 Norway country dynamics
Fig. 83 Norway market estimates and forecasts, 2018 - 2030
Fig. 84 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 85 China country dynamics
Fig. 86 China market estimates and forecasts, 2018 - 2030
Fig. 87 Japan country dynamics
Fig. 88 Japan market estimates and forecasts, 2018 - 2030
Fig. 89 India country dynamics
Fig. 90 India market estimates and forecasts, 2018 - 2030
Fig. 91 Thailand country dynamics
Fig. 92 Thailand market estimates and forecasts, 2018 - 2030
Fig. 93 South Korea country dynamics
Fig. 94 South Korea market estimates and forecasts, 2018 - 2030
Fig. 95 Australia country dynamics
Fig. 96 Australia market estimates and forecasts, 2018 - 2030
Fig. 97 Latin America market estimates and forecasts, 2018 - 2030
Fig. 98 Brazil country dynamics
Fig. 99 Brazil market estimates and forecasts, 2018 - 2030
Fig. 100 Argentina country dynamics
Fig. 101 Argentina market estimates and forecasts, 2018 - 2030
Fig. 102 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 103 South Africa country dynamics
Fig. 104 South Africa market estimates and forecasts, 2018 - 2030
Fig. 105 Saudi Arabia country dynamics
Fig. 106 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 107 UAE country dynamics
Fig. 108 UAE market estimates and forecasts, 2018 - 2030
Fig. 109 Kuwait country dynamics
Fig. 110 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 111 Market position of key market players- Circulating tumor cells market
Companies Mentioned
- QIAGEN
- Bio-Techne Corporation
- Precision Medicine Group, LLC.
- Bio-Rad Laboratories, Inc.
- Natera, Inc.
- Illumina, Inc.
- Cell Microsystems
- Greiner Bio One International GmbH
- Ikonisys Inc.
- Miltenyi Biotec
- Creative Bioarray
- BioFluidica
- Abnova Corporation
- Biolidics Limited
- Creatv MicroTech, Inc.
- LungLife AI, Inc.
- Epic Sciences
- Rarecells Diagnostics
- ScreenCell
- Menarini Silicon Biosystems
- APPLIED DNA SCIENCES, INC.
- Sysmex Corporation
- STEMCELL Technologies, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | March 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 12.62 Billion |
| Forecasted Market Value ( USD | $ 24.96 Billion |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
